A MULTIPOTENTIAL MITIGATION AGENT FOR GASTROINTESTINAL SYNDROME

承包商，在追求许可证，并根据FDA动物规则，将开发循环成纤维细胞生长因子-肽（FGF-P），一个拟议的生物更好的FgF-2，作为缓解剂辐射诱导的胃肠道毒性。FGF-P通过多种机制发挥作用，包括减少细胞损失和改善小肠粘膜增殖，改善肠道屏障功能，减少细菌移位，以及通过诱导粒细胞集落刺激因子（G-CSF）支持骨髓。

The Contractor, in pursuit of licensure and in accordance with the FDA Animal Rule, will develop circular fibroblast growth factor-peptide (FGF-P), a proposed bio-better of FgF-2, as a mitigation agent for radiation-induced GI toxicity. FGF-P acts through a variety of mechanisms, including decreased cell loss and improved proliferation of small bowel mucosa, improved gut barrier function with reduced bacterial translocation, and support of bone marrow with induction of granulocyte-colony stimulating factor (G-CSF).